title: [Comparative testing of Kamillosan cream and steroidal (0.25% hydrocortisone, 0.75% fluocortin butyl ester) and non-steroidal (5% bufexamac) dermatologic agents in maintenance therapy of eczematous diseases].
abstract: We report on 161 patients suffering from inflammatory dermatoses on hands, forearms, and lower legs who had been initially treated with 0.1% difluocortolone valerate. During the maintenance therapy carried out over a period of 3 to 4 weeks, we tested the efficacy of Kamillosan cream vs. 0.25% hydrocortisone, 0.75% fluocortin butyl ester, and 5% bufexamac in a bilateral comparative study. For the indications tested Kamillosan cream showed more or less equieffective therapeutic results as compared to 0.25% hydrocortisone. It is superior, however, to the non-steroidal anti-inflammatory agent 5% bufexamac as well as to 0.75% fluocortin butyl ester, a further glucocorticoid. With regard to neurodermitis, Kamillosan cream not only shows the same therapeutic effect as 0.25% hydrocortisone but is even of marked superiority towards other reference products.
authors.forename: P
authors.initials: P
authors.lastname: Aertgeerts
authors.forename: M
authors.initials: M
authors.lastname: Albring
authors.forename: F
authors.initials: F
authors.lastname: Klaschka
authors.forename: T
authors.initials: T
authors.lastname: Nasemann
authors.forename: R
authors.initials: R
authors.lastname: Patzelt-Wenczler
authors.forename: K
authors.initials: K
authors.lastname: Rauhut
authors.forename: B
authors.initials: B
authors.lastname: Weigl
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002019:Bufexamac / Q000008:administration & dosage* / Q000627:therapeutic use; D020843:Chamomile; D002986:Clinical Trials as Topic; D003872:Dermatitis / Q000188:drug therapy*; D003877:Dermatitis, Contact / Q000188:drug therapy; D012628:Dermatitis, Seborrheic / Q000188:drug therapy; D004060:Diflucortolone / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005448:Fluocortolone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage* / Q000627:therapeutic use; D006877:Hydroxamic Acids / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009450:Neurodermatitis / Q000188:drug therapy; D009822:Oils, Volatile / Q000627:therapeutic use*; D009824:Ointments; D010936:Plant Extracts / Q000627:therapeutic use*; D010946:Plants, Medicinal
chemical_list: D006877:Hydroxamic Acids; D009822:Oils, Volatile; D009824:Ointments; D010936:Plant Extracts; C013486:diflucortolone valerate; D002019:Bufexamac; D005448:Fluocortolone; C011824:fluocortin butyl ester; D004060:Diflucortolone; D006854:Hydrocortisone
vernacular_title: Vergleichende Prüfung von Kamillosan Creme gegenüber steroidalen (0,25% Hydrocortison, 0,75% Fluocortinbutylester) und nichtsteroidalen (5% Bufexamac) Externa in der Erhaltungstherapie von Ekzemerkrankungen.